XML 44 R10.htm IDEA: XBRL DOCUMENT v2.3.0.15
BUSINESS SEGMENT INFORMATION
9 Months Ended
Sep. 30, 2011
Segment Reporting [Abstract] 
Business Segment Information [Text Block]

Note 3. BUSINESS SEGMENT INFORMATION

 

The Company operates in a single BioPharmaceuticals segment which is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of innovative medicines that help patients prevail over serious diseases. A global research and development organization and a global supply chain organization are utilized and responsible for the development and delivery of products to the market. Products are distributed and sold through regional organizations that serve the United States; Europe; Latin America, Middle East, and Africa; Japan, Asia Pacific and Canada; and Emerging Markets defined as Brazil, Russia, India, China and Turkey. The business is also supported by global corporate staff functions. The segment information presented below is consistent with the financial information regularly reviewed by the chief operating decision maker for purposes of evaluating performance, allocating resources, setting incentive compensation targets, and planning and forecasting future periods.

 

Net sales of key products were as follows:

  Three Months Ended September 30, Nine Months Ended September 30,
Dollars in Millions2011 2010 2011 2010
PLAVIX*$ 1,788 $ 1,658 $ 5,415 $ 4,951
AVAPRO*/AVALIDE*  216   303   757   924
ABILIFY*  691   608   2,021   1,858
REYATAZ  391   375   1,153   1,105
SUSTIVA Franchise  359   342   1,073   1,008
BARACLUDE  311   228   878   667
ERBITUX*  172   159   510   497
SPRYCEL  211   144   576   407
YERVOY  121   -   216   -
ORENCIA  233   184   660   531
NULOJIX  -   -   2   -
ONGLYZA/KOMBIGLYZE  127   47   320   85
Mature Products and All Other  725   750   2,209   2,340
 Net Sales$ 5,345 $ 4,798 $ 15,790 $ 14,373

Segment income excludes the impact of significant items not indicative of current operating performance or ongoing results, and earnings attributed to Sanofi and other noncontrolling interest. The reconciliation to earnings before income taxes was as follows:

 Three Months Ended September 30, Nine Months Ended September 30,
Dollars in Millions2011 2010 2011 2010
BioPharmaceuticals segment income$ 1,347 $ 1,186 $ 3,934 $ 3,599
            
Reconciling items:           
Restructuring and other charges  (20)   (63)   (159)   (395)
Litigation (charges)/recoveries  -   (22)   102   (22)
Upfront, milestone and other licensing payments  (69)   -   (207)   (72)
In-process research and development (IPRD) impairment  (13)   -   (28)   -
Product liability charges  (10)   (13)   (36)   (13)
Noncontrolling interest  595   526   1,781   1,561
Earnings before income taxes$ 1,830 $ 1,614 $ 5,387 $ 4,658